GLP-3/RT vs IGF-1
GLP-3/RT and IGF-1 are studied in overlapping research areas, which is why they are frequently compared. This is a neutral side-by-side reference drawn from published preclinical literature and laboratory handling data.
How they actually differ
Comparing the two: GLP-3/RT is lipidated single-chain triple receptor agonist (gip / glp-1 / glucagon), while IGF-1 is 70-residue single-chain protein (native igf-1), three disulfide bonds — different molecular classes with different handling consequences; they call for different primary diluents (bacteriostatic water (0.9% benzyl alcohol) versus dilute acetic acid for initial dissolution); their leading degradation routes differ (interfacial aggregation from agitation, foaming, or freeze–thaw for GLP-3/RT, misfolding and irreversible denaturation for IGF-1), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.
GLP-3/RT — origin
GLP-3/RT is a rationally engineered single peptide chain designed to activate three receptors at once — GIP, GLP-1, and glucagon. It represents the third generation of incretin design: mono-agonists first, dual agonists such as GLP-2/Tirz second, and triagonists third. Adding glucagon-receptor activity is the conceptual leap, since glucagon signalling contributes energy expenditure rather than only appetite and glycaemic effects.
IGF-1 — origin
IGF-1 is the native insulin-like growth factor — a folded 70-amino-acid protein stabilised by three internal disulfide bonds. It is the downstream messenger produced after growth hormone acts, and it is handled as a protein rather than a short peptide. This is the native sequence, distinct from the long-acting LR3 analogue.
GLP-3/RT research themes
The defining feature: simultaneous GIP, GLP-1, and glucagon receptor activity from one chain.
Glucagon-receptor activity is studied for its contribution to energy expenditure, distinguishing triagonists from dual agonists.
Investigated in metabolic research models for effects on glucose homeostasis.
A major focus of the preclinical literature on this compound class.
IGF-1 research themes
Studied as the native ligand for the IGF-1 receptor and its downstream proliferation and survival pathways.
Examined in muscle research models for its role in satellite-cell behaviour and anabolic signalling.
Compared with IGF-1 LR3, whose reduced binding-protein affinity gives a longer active window — a contrast studied directly in the literature.
GLP-3/RT handling
- Never shake. Foam on a lipidated peptide solution is denatured material at the air–liquid interface, not a cosmetic issue.
- Introduce diluent slowly down the vial wall and allow the cake to dissolve without agitation, which may take several minutes.
- Do not freeze reconstituted solution — aggregation from freeze–thaw is irreversible.
- Faint opalescence at high concentration is expected; visible particulate is not.
IGF-1 handling
- Dissolve first in dilute acetic acid, then dilute into the working buffer — never expect plain water to take it up fully.
- Use a carrier protein and low-bind labware to prevent adsorptive loss.
- Aliquot for single use; do not re-freeze reconstituted protein.
Both third-party tested
Every Popular Peptides batch of GLP-3/RT and IGF-1 is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
GLP-3/RT reference
Related comparisons
GLP-3/RT and IGF-1 are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.